Ruby Meierotto, M.D.
Clinical Associate Professor
Department(s) of Radiology
Section: Breast Imaging
Saint Luke's Hospital
Education and Background
University of Texas - San Antonio
Residency - University of Kansas
Fellowship - Women's Imaging - University of Southern California
Meet Ruby Meierotto
Specialties and Research/Medical Interests
Ongoing Research Support:
R01 CA207445 (Behbod) 03/09/2017 – 02/28/2020 NIH
Identifying the Molecular and Cellular Basis of Invasive Phenotype in Human DCIS Major Goals: The purpose of this grant application is to improve the MIND models by mimicking the natural microenvironment of human DCIS in mice. Our ultimate goal is to increase the translation application of the DCIS MIND models.
R01CA172764 (multiPI:Cheng&Behbod) 09/01/2013 – 08/31/2018
Progression of DCIS to invasive breast cancer through CCR2 chemokine signaling Major Goals: To elucidate the role of CCR2/CCL2 signaling in DCIS progression to invasive breast cancer.
RSG-13-182-01-CSM (Cheng) 07/01/2013 – 06/30/2017
Am Cancer Society
Barriers to Breast Cancer Treatment Due to CCL2/CCR2 Chemokine Signaling
Major Goals: To understand (1) the role of CCR2 expression in breast cancer progression using mouse models, and (2) the mechanisms of CCR2 signaling in breast cancer cell survival and invasion.
R21 CA18789 (Behbod) 09/01/2014 – 08/31/2017
Elucidating Cellular Heterogeneity Among Cancer Stem Cells by Raman Spectroscopy Major Goals: to evaluate the use of Raman Tweezer Spectroscopy for sorting and characterizing tumor initiating cells by the expression of unique intracellular molecular composition. This new technology is expected to enable further enrichment of the most aggressive tumor cells and facilitate the future design of anti-cancer therapies for their eradication.
P30CA168524-suppl (Jensen) 03/03/2017 – 06/30/2017
NIH (suppl. to KU Cancer Center award)
MIND Models for Therapeutic Drug Testing Against Luminal B Breast Cancers Major Goals: 1. To establish at least 5 unique ER+ MIND xenograft models by intraductal injection of epithelial cells derived from patients’ luminal B breast cancer (HER2 negative) 2. To evaluate Ribociclib (LEE011; Novartis), a CDK4/6 inhibitor in combination with Letrozole, an aromatase inhibitor, in ER+ HER2 negative luminal B breast cancers.
Recently Completed Research Support:
R21CA185460 (Behbod) 05/01/2014 – 04/30/2017
NIH/NCI (no cost extension)
Essential Role of BCL9 in Promotion of Human DCIS to Invasive Ductal Carcinoma
Major Goals: To evaluate the role of nuclear vs. cytoplasmic BCL9 in promotion of DCIS invasive progression and in the formation of a DCIS pro-invasive stromal microenvironment by recruitment of macrophages.